日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

您現在的位置: > Language Tips > Audio & Video > Special Speed News  
 





  Once-daily pill could simplify HIV treatment
[ 2006-02-06 15:57 ]


I’m Steve Ember with the VOA Special English Health Report.


Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

Experts say more than forty million people around the world are living with H.I.V.

This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

Vocabulary

 

 

 
 
 




主站蜘蛛池模板: 亚洲第一区视频在线观看 | 久久伊99综合婷婷久久伊 | 另类视频色综合 | 免费在线看a | 国变精品美女久久久久av爽 | 亚洲欧美精品 | 成年人在线视频网站 | 操人视频免费 | 国产在线一区二区三区 | 国产精品婷婷午夜在线观看 | 国产人成精品一区二区三 | 国产精品一区视频 | 欧美日韩国产一区二区三区播放 | 亚洲第一成年免费网站 | 国产精品视频 | 国产精品成人一区二区 | 国产精品免费观看 | 中文字幕视频在线观看 | 草草久久久 | 色噜噜狠狠网站 | 久久精品中文字幕 | 九九国产在线视频 | 91精品免费观看 | 首页亚洲国产丝袜长腿综合 | 欧美性免费视频 | 国产原创视频在线 | 日韩午夜激情视频 | 欧美一区视频在线 | 日本视频免费高清一本18 | 2018中文字幕在线 | 亚洲一区精品在线 | 草草草影院 | 台湾佬中文娱乐2222vvv | 青青草国产 | 午夜资源| 国产精品久久久爽爽爽麻豆色哟哟 | 国产精品一区av | 性爱视频在线免费 | 日韩视频一区二区三区 | 天天激情 | 国产在线观看免费 |